$WT

WisdomTree (NYSE:WT) Delivers Strong Q2 CY2026 Numbers

Asset management firm WisdomTree (NYSE: WT) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 57.3% year on year to $177.2 million. Its non-GAAP profit of $0.31 per share was 17.3% above analysts’ consensus estimates. Is now the time to buy WisdomTree? Find out by accessing our full research report, it’s free. "The second quarter demonstrated the quality of WisdomTree's growth.

Original reporting
Published Jul 31, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 31, 2026, 11:58 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
WisdomTree (NYSE:WT) Delivers Strong Q2 CY2026 Numbers — source image
Decision brief

The 30-second read

$WTBullishMed
01

Why it matters

The disclosed beats on revenue and non-GAAP EPS, plus AUM growth to $162.9B, provide a concrete earnings-style catalyst for traders, though the immediate flat stock reaction tempers expectations.

02

Market read

Traders can reassess near-term valuation and momentum based on the reported Q2 beats and AUM expansion, but the lack of immediate price reaction suggests limited incremental surprise.

03

What to watch

The article flags that some quarter-to-quarter revenue comparisons can be distorted by outsized investment gains/losses, which could matter for interpreting the quality of growth.

Relevance 7/10Novelty 7/10Timing: post-Q2 results, published same day (2026-07-31)

Background

WisdomTree is an ETF and investment-products manager; the article frames Q2 CY2026 as its sixth consecutive quarter of record AUM.

Company-level read

Ticker impact

$WTBullishMedium confidence
Context

WisdomTree reported Q2 CY2026 revenue up 57.3% to $177.2M and non-GAAP EPS $0.31, beating consensus.

Expected impact

Likely modest upside follow-through versus peers if investors focus on margin expansion and AUM momentum; article notes shares were flat at $18.90 immediately after.

Evidence & confidence

The text provides multiple upside datapoints (revenue beat, EPS beat, AUM growth) but also says the stock was flat right after results, suggesting the market may have priced part of the move.

Market effects

ETF/asset managers may see read-across interest if growth and margin expansion narrative strengthens for the group.

No specific regional flows or mandates are disclosed beyond broad-based growth across regions.

Limited global spillover; the article is company-specific with no macro or regulatory catalyst.

Counterpoint

Despite beats, the stock reportedly stayed flat at $18.90 immediately after results, implying the market may question sustainability of the acceleration or margins.

Key entities

  • WisdomTree

    Reported Q2 CY2026 revenue, non-GAAP EPS, and AUM figures versus consensus.

  • Jonathan Steinberg

    CEO quote emphasizing broad-based AUM growth and operating discipline.

Related articles

$WTMed

WisdomTree (WT) Stock Is Up, What You Need To Know

WisdomTree (WT) stock rose 2.9% after Goldman Sachs increased its price target to $21.30, citing improved earnings and industry outlook. Shares later settled at $24.40, up 1.5% from the previous close. WT has seen volatility, with 11 moves over 5% in the past year. The stock is up 95% YTD, near its 52-week high of $25.04.

$WTMed

WT Maintained by Craig-Hallum -- Price Target Raised to $29.00

Craig-Hallum raised its price target for WisdomTree (WT) to $29.00 from $24.00, maintaining a 'Buy' rating. The stock is currently priced at $24.73, which GuruFocus deems 40.1% overvalued. WT has a GF Score™ of 82/100, showing strong performance but concerns over valuation. Insiders have sold $736,800 in shares recently, with no purchases.

$WTMed

WT Maintained by Goldman Sachs -- Price Target Raised to $21.30

Goldman Sachs maintained a Neutral rating on WisdomTree (WT) but raised its price target to $21.30 from $18.30. GuruFocus values WT at $17.65, suggesting a 41% overvaluation. The company has a GF Score of 82/100, with strong profitability and growth but low valuation metrics. Insiders have sold $736,800 worth of shares in the last three months.

$WTMed

Should You Buy WisdomTree (WT) Stock After Its Latest Crypto Move?

WisdomTree (WT) reported record AUM of $162.9B in Q2 2026, up 30% YoY, with revenue at $177.2M and 40.5% operating margin. The company partnered with MoonPay to integrate its tokenized fund WTGXX, accessing 35M accounts. Despite GAAP losses from debt repurchases, management highlights long-term growth potential in digital assets. WT trades at a forward P/E of 17.30.

$WTMed

WisdomTree Announces Second Quarter 2026 Results

WisdomTree, Inc. (WT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 WisdomTree Announces Second Quarter 2026 Results Record AUM of $162.9 Billion Diluted Earnings Per Share of $0.28; Adjusted Earnings Per Share of $0.31 13% Annualized Organic Flow Growth Rate Operating Margin Expanded by 780 bps Year over Year; or 900 bps, on an Adju

$WTMedAI 8/10

WisdomTree (WT) Launches Physical AI, Humanoids, Drones ETF (WDRN) Focused on Real-World Automation

WisdomTree (NYSE:WT) launched the Physical AI, Humanoids, and Drones ETF (WDRN) on May 14, targeting companies applying AI to physical tasks. The fund has a 0.45% expense ratio and focuses on humanoid robotics, autonomous drones, smart manufacturing, and logistics automation, using a rules-based, quarterly rebalanced index. The report says it aims to track the shift from digital AI to real-world automation.